Product Description: BLU-222 is an orally active and highly selective CDK2 inhibitor. BLU-222 disrupts Rb signaling and causes G1 arrest and apoptosis in CCNE1-amplified endometrial cancer cells[1][2][3].
Applications: Cancer-Kinase/protease
Formula: C15H17F2N7O2
References: [1]Talbot T, et al. Amplified therapeutic targets in high-grade serous ovarian carcinoma - a review of the literature with quantitative appraisal. Cancer Gene Ther. 2023 Jul;30(7):955-963./[2]House N, et al. BLU-222, a potent and highly selective CDK2 inhibitor, demonstrated antitumor activity as monotherapy and as combination treatment in CCNE1-aberrant endometrial cancer models[J]. Cancer Research, 2024, 84(6_Supplement): 1959-1959./[3]Luo L, et al. Abstract PO1-18-05: Combination treatment with CDK2 inhibitor (BLU-222) and either palbociclib or ribociclib is synergistic in pre-clinical models of CDK4/6 inhibitor-resistant breast cancer[J]. Cancer Research, 2024, 84(9_Supplement): PO1-18-05-PO1-18-05.
CAS Number: 2888704-84-3
Molecular Weight: 365.34
Compound Purity: 99.02
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Apoptosis;CDK
English
Deutsch
